| Therapeutic | Ramucirumab |
| Target | KDR |
| Heavy Chain | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS |
| Light Chain | DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK |
| 100% seqID Fv Structure | 3s34 [Fvs: HL], 3s36 [Fvs: HL], 3s37 [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3s34 [Fvs: HL] |
| 100% seqID Structure | 3s37 [Fvs: HL] |
| 100% seqID Structure | 3s36 [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | Dyax Human Phage Display |
| INN Year Proposed | 2008 |
| INN Year Recommended | 2009 |
| Companies Involved | Dyax, AstraZeneca, Dana-Farber Cancer Institute, Eli Lilly, Merck Sharp & Dohme, University of Texas M. D. Anderson Cancer Center, Washington University School of Medicine |
| Conditions Approved | Colorectal cancer, Gastric cancer, Non-small cell lung cancer, Liver cancer |
| Conditions Active | Oesophageal cancer, Urogenital cancer, Biliary cancer, Carcinoid tumour, Solid tumours, Pancreatic cancer |
| Conditions Discontinued | Breast cancer, Malignant melanoma, Ovarian cancer, Prostate cancer, Renal cell carcinoma |
| Notes |
